Vitamin D in MS: A vitamin for 4 seasons

Neurology

Volumn 79, Issue 3, 2012, Pages 208-210

  Ascherio, Alberto ^a,b   Marrie, Ruth Ann ^c  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; BETA INTERFERON; CALCITRIOL; ERGOCALCIFEROL; VITAMIN D; VITAMIN D RECEPTOR;

DISABILITY; DISEASE ACTIVITY; DRUG MEGADOSE; DRUG SAFETY; EDITORIAL; HUMAN; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RELAPSE; RISK ASSESSMENT; SUN EXPOSURE; ULTRAVIOLET B RADIATION; VITAMIN D DEFICIENCY;

EID: 84866064060     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31825fe131     Document Type: Editorial

References (16)

1. Runia TF, Hop W C J, De Rijke YB, Buljevac D, Hintzen RQ. Lower serum vitamin D levels are associated with a higher relapse risk in multiple sclerosis. Neurology 2012;79:261-266.
2. Løken-Amsrud KI, Holmøy T, Bakke SJ, et al. Vitamin D and disease activity in multiple sclerosis before and during interferon-β treatment. Neurology 2012;79:267-273.
3. Stewart N, Simpson S Jr, Van Der Mei I, et al. Interferon-β and serum 25-hydroxyvitamin D interact to modulate relapse risk in MS. Neurology 2012;79:254-260.
4. Simpson S Jr, Taylor B, Blizzard L, et al. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol 2010;68:193-203.
5. Ascherio A, Munger KL, Simon KC. Vitamin D and multiple sclerosis. Lancet Neurol 2010;9:599-612.
6. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006;296:2832-2838.
7. Banwell B, Bar-Or A, Arnold DL, et al. Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study. Lancet Neurol 2011;10:436-445.
8. Ramagopalan SV, Dyment DA, Cader MZ, et al. Rare variants in the CYP27B1 gene are associated with multiple sclerosis. Ann Neurol 2011;70:881-886.
9. Smolders J, Peelen E, Thewissen M, et al. Safety and T cell modulating effects of high dose vitamin D3 supplementation in multiple sclerosis. PLoS One 2010;5:e15235.
10. Kimball S, Vieth R, Dosch HM, et al. Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis. J Clin Endocrinol Metab 2011;96:2826-2834.
11. Bischoff-Ferrari HA, Shao A, Dawson-Hughes B, Hathcock J, Giovannucci E, Willett WC. Benefit-risk assessment of vitamin D supplementation. Osteoporos Int 2010;21:1121-1132.
12. Stein MS, Liu Y, Gray OM, et al. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology 2011;77:1611-1618.
13. Smolders J, Hupperts R, Barkhof F, et al. Efficacy of vitamin D (3) as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: A Phase II, multicenter, double-blind, randomized, placebocontrolled trial. J Neurol Sci 2011;311:44-49.
14. Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux MJ. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 2003;77:204-210.
15. Sanders KM, Stuart AL, Williamson EJ, et al. Annual highdose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA 2010;303:1815-1822.
16. Marcus JF, Shalev SM, Harris CA, Goodin DS, Josephson SA. Severe hypercalcemia following vitamin D supplementation in a patient with multiple sclerosis: a note of caution. Arch Neurol 2012;69:129-132.